Related Experiment Video
Updated: Dec 19, 2025

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
David E Gordon1,2,3,4, Gwendolyn M Jang1,2,3,4, Mehdi Bouhaddou1,2,3,4
1QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.
Researchers mapped interactions between SARS-CoV-2 (novel coronavirus) and human proteins. They identified 67 druggable human proteins targeted by existing drugs, offering potential COVID-19 treatments.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- The novel coronavirus SARS-CoV-2 causes COVID-19, leading to a global health crisis with no approved treatments.
- Understanding the molecular mechanisms of SARS-CoV-2 infection is crucial for developing effective therapies.
Purpose of the Study:
- To identify SARS-CoV-2-human protein-protein interactions (PPIs).
- To discover host factors targeted by existing drugs for potential COVID-19 therapeutic development.
Main Methods:
- Cloned, tagged, and expressed 26 SARS-CoV-2 viral proteins in human cells.
- Utilized affinity-purification mass spectrometry (AP-MS) to identify host-virus PPIs.
- Screened identified host factors for druggability with existing pharmaceuticals.
Main Results:
- Identified 332 high-confidence SARS-CoV-2-human PPIs.
- Discovered 67 druggable human proteins associated with SARS-CoV-2 infection.
- Found 69 FDA-approved drugs, clinical trial candidates, and preclinical compounds targeting these host factors.
Conclusions:
- Mapping SARS-CoV-2-human PPIs reveals critical host dependency factors.
- Targeting these host factors with existing drugs presents a promising strategy for developing broad-acting antiviral therapeutics against coronaviruses.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Related Concept Videos
Protein-protein Interfaces
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Single Nucleotide Polymorphisms-SNPs
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...